Stockscreener 앱 받기
0.895
7.48%
0.0623
전일 마감가:
$0.8327
열려 있는:
$0.871
하루 거래량:
215.80K
Relative Volume:
1.48
시가총액:
$14.24M
수익:
$345.00K
순이익/손실:
$-11.25M
주가수익비율:
-1.2401
EPS:
-0.7217
순현금흐름:
$-16.70M
1주 성능:
-9.60%
1개월 성능:
-22.51%
6개월 성능:
-27.82%
1년 성능:
-38.06%
1일 변동 폭
$0.821
$0.92
1주일 범위
$0.80
$0.99
52주 변동 폭
$0.7687
$1.8395
Allarity Therapeutics Inc Stock (ALLR) Company Profile
명칭
Allarity Therapeutics Inc
전화
401-426-4664
주소
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.895 | 14.24M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 개시 | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - GlobeNewswire Inc.
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket - Benzinga
Allarity Therapeutics files for $100 million SPAC offering By Investing.com - Investing.com Australia
Allarity Therapeutics files for $100 million SPAC offering By Investing.com - Investing.com South Africa
Allarity Therapeutics files for $100 million SPAC offering - Investing.com
Allarity Therapeutics files for $100 million SPAC offering By Investing.com - Investing.com India
A former Novo Nordisk president will chair Allarity’s new acquisition company. The proposed offering is $100 million. - Stock Titan
Allarity Therapeutics Stock Price Forecast. Should You Buy ALLR? - StockInvest.us
Allarity Therapeutics Inc (ALLR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Allarity Therapeutics Inc (ALLR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Allarity Therapeutics Inc (ALLR) Peer Comparison – Compare with Others - Value Research
Allarity Therapeutics Inc (ALLR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Allarity (ALLR) Financial Update: EPS Clears the Reported Estimate in the Latest Session; Trading Response: The Stock Closes Near Unchanged at the CloseEBITDA Estimate Trend - vinanet.vn
Allarity (ALLR) Earnings Update: The Available Earnings Metric Delivers a Beat; Price Move: Shares Move 5.93% Higher for the Current SessionEarnings Seasonality - vinanet.vn
Allarity Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Investing News Network
Allarity Therapeutics Q2 EPS of $(0.21) beats $(0.25) estimate - scanx.trade
Allarity Therapeutics reports Q2 results, cash position - Investing.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - The Manila Times
Allarity Therapeutics, Inc. 2026: Revenue $0 Net income ($3.41M), EPS ($0.21) — 10-Q Summary - TradingView
Allarity Therapeutics reports Q2 results, cash position By Investing.com - Investing.com Canada
Allarity Therapeutics (ALLR) adds $20M debt, holds $26.9M cash in Q2 2026 - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready ... - Caledonian Record
Patent Gives Allarity’s Cancer-Drug Pairing Exclusivity Into 2042 - Stock Titan
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Reports Second Quarter 2026 Results - GlobeNewswire
Allarity Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss of -$0.17 Highlights Cost DisciplineEarnings Power Value - vinanet.vn
Allarity Therapeutics (ALLR) Edges Higher: Biotech Stock Tests Key $1.42 Resistance After +1.5% MoveVolume Oscillator - dars.gov.et
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Allarity Therapeutics (ALLR) Gains 2.48% as Stock Holds Above Key Support ZoneDividend ETF - dars.gov.et
Allarity Therapeutics (ALLR) Gains 2.48% as Stock Holds Above Key Support ZoneVOLD Alert - vinanet.vn
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics (ALLR) Slips 1.65% as Stock Tests Key Support LevelsMoving Average Ribbon - vinanet.vn
Allarity Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLR - TradingView
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190| - TradingKey
TradingKey - TradingKey
Allarity Therapeutics Inc (ALLR) Income Statement - TradingKey
ALLR Q1 2026 Earnings: EPS Beat by 24.24% as Pre-Revenue Biotech Faces Market SkepticismEarnings Analysis - vinanet.vn
Allarity Therapeutics Inc (ALLR) News, Articles, Events & Latest Updates - Stocktwits
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance Australia
Allarity Therapeutics Inc (ALLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):